In the preceding three months, 4 analysts have released ratings for Hims & Hers Health (NYSE:HIMS), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 1 | 1 | 1 | 0 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 1 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $40.5, a high estimate of $60.00, and a low estimate of $21.00. Highlighting a 27.03% decrease, the current average has fallen from the previous average price target of $55.50.
Decoding Analyst Ratings: A Detailed Look
A comprehensive examination of how financial experts perceive Hims & Hers Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Allen Lutz | B of A Securities | Lowers | Underperform | $21.00 | $26.00 |
| David Larsen | BTIG | Lowers | Buy | $60.00 | $85.00 |
| Mark Mahaney | Evercore ISI Group | Announces | In-Line | $33.00 | - |
| Glen Santangelo | Barclays | Announces | Overweight | $48.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hims & Hers Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Hims & Hers Health compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Hims & Hers Health's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Hims & Hers Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Hims & Hers Health analyst ratings.
Delving into Hims & Hers Health's Background
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Hims & Hers Health: Financial Performance Dissected
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Hims & Hers Health's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 49.16%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Hims & Hers Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.63%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Hims & Hers Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.76%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Hims & Hers Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.77%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Hims & Hers Health's debt-to-equity ratio surpasses industry norms, standing at 1.92. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
- No comments yet. Be the first to comment!